ArticleJournal of the advanced practitioner in oncology2026
Blazing Trails With Research: Paving the Way for Advanced Practice Providers.
Article in Journal of the advanced practitioner in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In September 2021, the National Cancer Institute (NCI) expanded the ability for advanced practice providers (APP) to practice more autonomously by being able to write orders for research-related anti-cancer therapy. Objectives: The goal was to align with NCI guidance to permit APPs to independently write non-Cycle 1 Day 1 study agent orders. Methods: An academic institution created a process to comply with the NCI's memorandum. Health-system policy was updated to reflect this new capability. A tracking system was established to monitor NCI's Registration and Credentialing Roster (RCR) expiration dates. An audit process was created to verify alignment between signed electronic research-related anti-cancer therapy orders and Delegation of Tasks Logs. Results: To date, no adverse comments about APPs' abilities to sign anti-cancer trial orders have been received from organizations that accredit or support clinical trials. In addition, no APPs have lost the ability to sign anti-cancer therapy orders because they failed to renew their RCR within the expiration period. To facilitate this capability in a timely manner, a research-specific onboarding experience was created. Conclusion: APPs may safely write anti-cancer treatment orders for patients enrolled in clinical trials. Additionally, such privilege may contribute to the enhanced participation of APPs through research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.